Opinion|Videos|July 8, 2024
Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the CDK4/6i options?
- Please briefly review the main clinical trials and recent data.
- How do the data for the 3 CDK4/6i compare?
Advertisement
Related to this article
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/19
2
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
3
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5